ライフサイエンスコーパス: non-muscle

1 ephosphorylates the RLC in smooth muscle and non-muscle.

2 Here, we demonstrate that the non-muscle ~214-kDa myosin light chain (MLC) kinase (nmM

3 to rabbit skeletal muscle (alpha) and human non-muscle (85% beta, 15% gamma) actin filaments from th

4 inst a human cDNA library and identified the non-muscle actin filament cross-linking protein filamin

5 Here we reconstitute assembly of mammalian, non-muscle actin filaments from physiological concentrat

6 When non-muscle actin is used, FRLalpha-C's effects are large

7 a(cyto)-actin can likely build all essential non-muscle actin-based cytoskeletal structures including

8 erent from that of filaments containing beta-non-muscle actin.

9 The two non-muscle actins, beta- and gamma-, are ubiquitously pr

10 governing the specification and function of non-muscle actomyosin structures, such as contractile ri

11 pically co-express ACTN4 and ACTN1, a second non-muscle alpha-actinin gene.

12 stoma cell variants which encodes the second non-muscle alpha-actinin isoform designated ACTN4 (actin

13 Recombinant TM5a, a short non-muscle alpha-tropomyosin, inhibited depolymerization

14 tribution of CeMyoD to specification of both non-muscle and muscle fates.

15 Unlike most vertebrate non-muscle and smooth muscle myosin IIs, baculovirus-exp

16 The interaction of profilin and non-muscle beta,gamma-actin prepared from bovine spleen

17 Here, we examine the role of "non-muscle" caveolins (Cav-1 and Cav-2) in skeletal musc

18 Non-muscle cell contractility is critical for tissues to

19 step in the initiation of smooth muscle and non-muscle cell contraction.

20 other SH3-containing proteins in muscle and non-muscle cell extracts were validated with peptide arr

21 n cell lineages are normally established and non-muscle cell fate markers begin to be expressed.

22 ssion of c6orf32 in C2C12 or HEK293 cells (a non-muscle cell line) promoted formation of long membran

23 nd differentiation of the diverse muscle and non-muscle cell lineages of the heart.

24 iadin-1 as a series of glycoform variants in non-muscle cell lines and neonatal heart cells using pla

25 Finally, we confirmed in non-muscle cell lines that TBK1 phosphorylation occurs i

26 nsitization of smooth muscle contraction and non-muscle cell motility is through inhibition of the sm

27 ity without transdifferentiation to multiple non-muscle cell types and tested dystrophin restoration

28 In non-muscle cell types, lysosomes are critical mediators

29 and smooth muscle differentiation markers in non-muscle cell types.

30 ed muscles, 16 non-striated muscles, and two non-muscle cells (coelomocytes).

31 sassembly of the actin-based cytoskeleton in non-muscle cells and clears the circulation of filaments

32 for global actin cytoskeleton remodeling in non-muscle cells and provide insight into cellular respo

33 s the presence of a skelemin-like protein in non-muscle cells and provides evidence that it may be in

34 lso binds to F-actin in smooth muscle and in non-muscle cells and stabilizes and regulates the filame

35 Adhesion and morphogenesis of many non-muscle cells are guided by contractile actomyosin bu

36 Transdifferentiation of human non-muscle cells directly into myogenic cells by forced

37 ac myocytes, C2C12 myotubes, and transfected non-muscle cells expressing alpha1 subunits.

38 ed by exon 9d expressed in smooth muscle and non-muscle cells increases the affinity of unacetylated

39 division of mesodermal cells into muscle and non-muscle cells is crucial to animal development.

40 normally in muscle cells and ectopically in non-muscle cells is dependent upon the integrity of the

41 percentage of arginylated actin in migratory non-muscle cells under different physiological condition

42 new regulatory pathway in smooth muscle and non-muscle cells whereby ROCK1 phosphorylates and regula

43 In non-muscle cells, a shorter CaD isoform co-exists with m

44 ulate the contractility of smooth muscle and non-muscle cells, and there is evidence that this occurs

45 n mouse myogenic cells, we found that, as in non-muscle cells, Bax co-immunoprecipitated with the mul

46 activity of myosin II, in smooth muscle and non-muscle cells, by modulating the Ca2+ sensitivity of

47 In non-muscle cells, CHC22 localizes to perinuclear vesicul

48 al component of caveolae membrane domains in non-muscle cells, including mammary epithelia.

49 t high levels in muscle and at low levels in non-muscle cells, relative to CHC17.

50 myosin (RLC) controls motility of mammalian non-muscle cells, the functional significance of RLC pho

51 actin filaments from overgrowing, whereas in non-muscle cells, their function has remained elusive.

52 to caffeine and halothane when expressed in non-muscle cells, their influence on EC coupling can onl

53 wo mutations inhibit myosin self-assembly in non-muscle cells, they do not prevent incorporation of t

54 trast to their role in muscle myofibrils, in non-muscle cells, Tmods bind actin-tropomyosin filaments

55 ogene has been shown to induce myogenesis in non-muscle cells, to promote muscle hypertrophy in postn

56 In non-muscle cells, tropomyosin additionally controls acce

57 Among multiple TMs expressed in non-muscle cells, tropomyosin-1 (TM1) isoform induces st

58 In smooth muscle and non-muscle cells, where troponin is absent, the precise

59 olin-1 is required for caveolae formation in non-muscle cells, while the expression of caveolin-3 dri

60 l for the regulation of actin homeostasis in non-muscle cells.

61 nd MEF2C stimulate RGMc promoter function in non-muscle cells.

62 l building blocks of the cytoskeleton in all non-muscle cells.

63 functional roles of actomyosin in muscle and non-muscle cells.

64 length of actin filaments in both muscle and non-muscle cells.

65 ), and is also associated with cell cycle in non-muscle cells.

66 ochemical characteristics of both muscle and non-muscle cells.

67 d for different actin dynamics in muscle and non-muscle cells.

68 -calponin is found in both smooth muscle and non-muscle cells.

69 y components of contractile stress fibers in non-muscle cells.

70 activate this enhancer in some, but not all, non-muscle cells.

71 pha-MHC gene by preventing its expression in non-muscle cells.

72 s a silencer of alpha-MHC gene expression in non-muscle cells.

73 iation program when ectopically expressed in non-muscle cells.

74 tural basis of its functioning in muscle and non-muscle cells.

75 cle cells, despite substantial DNA uptake by non-muscle cells.

76 ntraction and other contractile processes in non-muscle cells.

77 ecting a subset of both striated muscles and non-muscle cells.

78 ed muscles, 16 non-striated muscles, and two non-muscle cells.

79 by rapid cytoskeletal rearrangement, even in non-muscle cells.

80 the mechanical function of alpha-actinin in non-muscle cells: alpha-actinin-microinjected cells are

81 an myosin complement have been identified as non-muscle class II myosins.

82 formation of striated body wall muscles and non-muscle coelomocytes.

83 Non-muscle contraction is widely believed to be mediated

84 scence microscopy, we show that tropomyosin (non-muscle Drosophila Tm1A) polymerizes along actin fila

85 To investigate the function of the major non-muscle dystrophin isoform, Dp71, we substituted a be

86 anslationally active in Escherichia coli and non-muscle eukaryotic cells, producing the expected trun

87 and stimulates inclusion of the alternative non-muscle exon.

88 differ internally by exons 6a/6b and possess non-muscle exons 1b/9d at the termini, hence they lack t

89 study we cloned and characterized muscle and non-muscle factors that bind to this element.

90 A-1, function synergistically to promote the non-muscle fate in cells also competent to form muscles.

91 aling, whereas 21 proteins, including myosin non-muscle form A, annexin 2, annexin A6, and Hsp47 were

92 found in the ocular primordia and muscle and non-muscle forming tissues of the eyes.

93 Introduction of the non-muscle Galphas isoform, GalphasXL elicited hypertrop

94 Six point mutations in non-muscle gamma-actin at the DFNA20/26 locus cause auto

95 egulates skeletal muscle genes and represses non-muscle genes through affecting regional epigenetic m

96 enes targeted by miR-200a, we focused on the non-muscle heavy chain IIb (NMHCIIb), and showed that mi

97 ell currents in muscle-type (TE671/CN21) and non-muscle (HEK293) cell lines expressing either fetal o

98 protein markers may have prognostic value in non-muscle invasive bladder cancer for guiding optimal t

99 ight component and the protocol for treating non-muscle invasive bladder cancer.

100 nother six patients (14%) were downstaged to non-muscle invasive disease.

101 Patients with high-risk non-muscle invasive tumors that do not respond to adjuva

102 ive multi-center transcriptional analysis of non-muscle invasive urothelial bladder cancer.

103 three different tissue microarrays with 693 non-muscle invasive urothelial carcinomas from Danish, S

104 er cancer with worse clinical prognosis from non-muscle-invasive (superficial) cancer, has significan

105 he primary tumor site showed no (T0) or only non-muscle-invasive (T1) residual tumor.

106 muscle-invasive (T2-T4 stage) compared with non-muscle-invasive (Ta, T1 stage) bladder cancer (case-

107 dder cancer and can be categorized as either non-muscle-invasive (Ta-T1) or muscle-invasive (T2).

108 The majority of bladder cancers are non-muscle-invasive at presentation; however, the recurr

109 To assess effect on recurrence, we grouped non-muscle-invasive BC patients according to intravesica

110 In patients with non-muscle-invasive BC, the variant IL-6 genotype was as

111 tion of bladder cancer improves detection of non-muscle-invasive bladder cancer (NMIBC) and reduces r

112 Purpose Many patients with high-risk non-muscle-invasive bladder cancer (NMIBC) are either re

113 med the overexpression of fibulin-3 in T2 vs non-muscle-invasive bladder cancer (NMIBC) by quantitati

114 Non-muscle-invasive bladder cancer (NMIBC) is a highly r

115 Non-muscle-invasive bladder cancer (NMIBC) remains one o

116 Patients with intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) without carci

117 recurrence and progression in patients with non-muscle-invasive bladder cancer (NMIBC).

118 ged 18 years or older, with BCG-unresponsive non-muscle-invasive bladder cancer and an Eastern Cooper

119 not meet the definition of BCG-unresponsive non-muscle-invasive bladder cancer and were therefore ex

120 Non-muscle-invasive bladder cancer embraces a spectrum o

121 ladder cancer is the highest risk subtype of non-muscle-invasive bladder cancer with unpredictable ou

122 For non-muscle-invasive bladder cancer, the mainstay of trea

123 ay of therapy for intermediate and high-risk non-muscle-invasive bladder cancer, the therapeutic opti

124 ladder cancer is the highest risk subtype of non-muscle-invasive bladder cancer, with highly variable

125 el intravesical therapy for BCG-unresponsive non-muscle-invasive bladder cancer.

126 CR) gene signature to predict progression in non-muscle-invasive bladder cancer.

127 s the surgical mainstay for the treatment of non-muscle-invasive bladder cancer.

128 is the most effective therapy for high-risk non-muscle-invasive bladder cancer.

129 isk ratio, in patients with BCG-unresponsive non-muscle-invasive bladder cancer.

130 s efficacy in patients with BCG-unresponsive non-muscle-invasive bladder cancer.

131 ne QPCR panel to help predict progression of non-muscle-invasive bladder cancers and delineate a syst

132 ict the progression of a subset of recurring non-muscle-invasive cancers.

133 and 10-year estimates of muscle-invasive LF, non-muscle-invasive LF, and DM were 13% and 14%, 31% and

134 specific survival (DSS), muscle-invasive and non-muscle-invasive local failure (LF), and distant meta

135 -invasive bladder cancers, are classified as non-muscle-invasive or 'superficial' tumours.

136 Non-muscle-invasive tumors are treated with endoscopic r

137 d for carcinoma in situ and other high grade non-muscle-invasive tumours.

138 Accurate grading of non-muscle-invasive urothelial cell carcinoma is of majo

139 th bladder tumors (either muscle-invasive or non-muscle-invasive).

140 Dp116 is a non-muscle isoform of dystrophin that assembles the dyst

141 The ADF-like non-muscle isoform UNC-60A had greater activities to cau

142 n platelets is identical to the cytoskeletal/non-muscle isoform.

143 domain in Ca(2+)-dependent actin binding of non-muscle isoforms.

144 smooth muscle-specific caldesmon (h-CaD) and non-muscle (l-CaD) by Western blotting, RT-PCR, and real

145 r dystrophy, little is known regarding their non-muscle lineage choices or whether the dystrophic mus

146 Actin, Troponin I, and Myosin Light Chain in non-muscle lineages.

147 the specification and differentiation of the non-muscle mesodermal cells, the coelomocytes (CCs).

148 tivation did not affect cell contribution to non-muscle mesodermal lineages, including fibroblasts an

149 ctin-linked' regulation of smooth muscle and non-muscle Mg(2+) actin-activated myosin II ATPase activ

150 This study addressed the role of non-muscle myosin (NM) IIA in two different modes of epi

151 smooth muscle (to regulate contraction) and non-muscle myosin (to regulate non-apoptotic cell death)

152 ccumulate different amounts of active apical non-muscle myosin 2 depending on the distance from the v

153 Additionally, blocking Rho and non-muscle myosin attenuated MT1-MMP-induced phenotypic

154 Here we show the identification of non-muscle myosin heavy chain 9 (MYH9) as an essential f

155 en a candidate gene in this region, encoding non-muscle myosin heavy chain A (MYH9), for mutations in

156 gene-trapped ES cell lines specific for the non-muscle myosin heavy chain class IIA or myosin heavy

157 Mass spectrometry analysis revealed that non-muscle myosin heavy chain II A (NMHC IIA) is a prote

158 al cell-specific alternative splicing of the non-muscle myosin heavy chain II-B pre-mRNA as a model.

159 ive splicing of a cassette exon, N30, in the non-muscle myosin heavy chain II-B pre-mRNA, previously

160 associated with rat liver mitochondrial DNA: non-muscle myosin heavy chain IIA and beta-actin.

161 radient analysis suggest some beta-actin and non-muscle myosin heavy chain IIA reside within human mi

162 , transient gene silencing of MYH9 (encoding non-muscle myosin heavy chain IIA), or the closely relat

163 or the closely related MYH10 gene (encoding non-muscle myosin heavy chain IIB), altered the topology

164 n (MLC), and the IIA and IIB isoforms of the non-muscle myosin heavy chain in rat IMCD cells.

165 Cs and intact CPAs expressed h-caldesmon and non-muscle myosin heavy chain-2; phenotypic markers of c

166 cells polarize to anisotropic features under non-muscle myosin II (MII) inhibition, despite MII ordin

167 s, this remodelling requires the activity of non-muscle myosin II (MyoII) in the interphasic cells ne

168 ired to power these changes are generated by non-muscle myosin II (MyoII) motor proteins pulling fila

169 proteins that triggers rapid and reversible non-muscle myosin II (NM II) dependent contraction of th

170 the neuroepithelium is tightly regulated by non-muscle myosin II (NMII) activity, we tested the role

171 We find that actin and non-muscle myosin II (NMII) assemble into previously und

172 Active non-muscle myosin II (NMII) enables migratory cell polar

173 Inhibition of non-muscle myosin II (NMII) enhances central but impairs

174 s establishes the critical role of ezrin and non-muscle myosin II (NMII) in the progressive implement

175 Non-muscle myosin II (NMII) is a conserved force-produci

176 Non-muscle myosin II (NMII) is reported to play multiple

177 lls, this process depends on the activity of non-muscle myosin II (NMII), a family of actin-binding m

178 that treatment with a specific inhibitor of non-muscle myosin II (NMII), blebbistatin, enhances the

179 Non-muscle myosin II (NMII)-induced multicellular contra

180 copy, we analyzed the localization of axonal non-muscle myosin II (NMII).

181 ile forces generated by the molecular motor, non-muscle myosin II (NMII).

182 t localization of both canonical anillin and non-muscle myosin II (NMM-II) to intercellular bridges.

183 dentified an interaction between CLPTM1L and non-muscle myosin II (NMM-II), a protein involved in mai

184 Here we have investigated the role of non-muscle myosin II (nmy-2) in these asymmetric divisio

185 Interfering with non-muscle myosin II (referred to as Myosin II) activity

186 ctive protrusions where F-actin is devoid of non-muscle myosin II activity.

187 Inhibition of non-muscle myosin II also resulted in a disruption of ME

188 Additionally, we show that non-muscle Myosin II and the polarity proteins Discs lar

189 Particularly, we identified non-muscle myosin II as an important factor in Kv2.1 tra

190 evidence for an involvement of cadherins and non-muscle myosin II as downstream components controllin

191 tension of actin cytoskeleton by inhibiting non-muscle myosin II ATPase decreased h2-calponin expres

192 Here we show that non-muscle myosin II has a direct role in actin network

193 able to substitute partially for endogenous non-muscle myosin II heavy chain in animals lacking zygo

194 ant phenotypes when introduced into the sole non-muscle myosin II heavy chain in Drosophila melanogas

195 nsfer assay, that assembly of the Drosophila non-muscle myosin II heavy chain, zipper, is mediated by

196 Although, the non-muscle myosin II holoenzyme (myosin) is a molecular

197 naling in IMCD cells and point to a role for non-muscle myosin II in regulation of water permeability

198 The motor protein non-muscle myosin II is a major driver of the movements

199 Non-muscle myosin II is found adjacent to mitochondria b

200 The activity of smooth muscle/non-muscle myosin II is regulated by phosphorylation of

201 Non-muscle myosin II is shown to be expressed in a patte

202 Two of the three human non-muscle myosin II isoforms (IIA and IIB) have been in

203 Here, we investigated the role of non-muscle myosin II isoforms (NMIIA and NMIIB) in epith

204 Non-muscle myosin II isoforms thus appear to have distin

205 In spite of the presence of multiple non-muscle myosin II isoforms, we demonstrate that a sin

206 used by upregulation of Rho-kinase-dependent non-muscle myosin II motor activity.

207 hanisms of wild-type and the S237C mutant of non-muscle myosin II motor from Dictyostelium discoideum

208 th increasing shear stress and inhibition of non-muscle myosin II motors, respectively.

209 horylation and signalling cascade, including non-muscle myosin II redistribution and co-localization

210 Preconstriction is facilitated by actin and non-muscle myosin II through a mechanism that remains un

211 ant heavy chains resulted in D. melanogaster non-muscle myosin II with partial wild-type function.

212 These data reveal that the activity of non-muscle myosin II, a critical molecule of cellular co

213 atively regulates the mono-ubiquitination of non-muscle Myosin II, a protein associated with hearing

214 Here, we show that non-muscle myosin II, alpha-actinin, and filamin accumul

215 genesis depends on the correct regulation of non-muscle Myosin II, but how this motor protein is spat

216 n (RLC) phosphorylation activates smooth and non-muscle myosin II, but it has not been established if

217 We find that a single non-muscle myosin II, NMIIB, is required for meiotic cyt

218 re known to express at least two isoforms of non-muscle myosin II, referred to as myosin IIA and myos

219 e midzone (midzone MTs), whereas F-actin and non-muscle myosin II, together with other factors, organ

220 r apicomedial accumulation of Rho kinase and non-muscle myosin II, which coordinate apical constricti

221 Myh9, the non-muscle myosin II-A heavy chain, was enriched in immu

222 e interaction of RLC with the neck region of non-muscle myosin II-B (NMII-B) heavy chain; NR-RLC inte

223 We report a novel isoform of non-muscle myosin II-C (NM II-C), NM II-C2, that is gene

224 light chain kinase (MLCK) and regulation of non-muscle myosin II.

225 gh its ability to phosphorylate and activate non-muscle myosin II.

226 ulating cortical actomyosin activity through non-muscle myosin II.

227 We identify the heavy chain of the non-muscle myosin IIA (NMHC-IIA) as being phosphorylated

228 ic analysis revealed that EphA3 ICD binds to non-muscle myosin IIA (NMIIA) and increases its phosphor

229 and results in the S1943 phosphorylation of non-muscle Myosin IIA (NMIIA) heavy chain, thus facilita

230 ase (MLCK), culminating in the activation of non-muscle myosin IIA (NMIIA).

231 ng coordinates the dynamic redistribution of non-muscle myosin IIA and beta2-integrin, which facilita

232 ut increases the interaction of C2GnT-M with non-muscle myosin IIA and its transportation to the endo

233 +) supplementation or chemical inhibition of non-muscle myosin IIA heavy chain activity.

234 e report the kinetic characterization of the non-muscle myosin IIA isoform.

235 s, alpha-actinin cross-linking proteins, and non-muscle myosin IIA mini-filaments.

236 Similar to non-muscle myosin IIB, non-muscle myosin IIA shows high ADP affinity and little

237 This implies that non-muscle myosin IIA spends only a small fraction of it

238 MYH9 encodes the heavy chain of non-muscle myosin IIA, a cellular motor involved in moti

239 e Giantin site and is recycled by binding to non-muscle myosin IIA, a motor protein, via the cytoplas

240 ine TM cells contained Plectin 1, Filamin A, non-muscle myosin IIA, clathrin, alpha-actinin, vimentin

241 Non-muscle myosin IIB (NMIIB) generates tension along ac

242 hed new light on the mechanism, showing that non-muscle myosin IIb is intimately involved.

243 Transient kinetics of non-muscle myosin IIB showed that this motor has a very

244 port the kinetic characterization of a human non-muscle myosin IIB subfragment-1 construct produced i

245 Thus, non-muscle myosin IIB subfragment-1 spends a significant

246 In contrast, genetic ablation of non-muscle myosin IIB was associated with a 60% decrease

247 Similar to non-muscle myosin IIB, non-muscle myosin IIA shows high

248 actin-bound states, which is in contrast to non-muscle myosin IIB.

249 al protein kinase C, a negative regulator of non-muscle myosin IIB.

250 The role for non-muscle myosin in cell motility was controversial, bu

251 nset of the establishment phase involves the non-muscle myosin NMY-2 and the 14-3-3 protein PAR-5.

252 ents of muscle myosin subfragment 1 (S1) and non-muscle myosin V (MV).

253 lasts that were immunoreactive for vimentin, non-muscle myosin, and fibronectin, but not for alpha-sm

254 /3 or its activators changes the dynamics of non-muscle myosin, NMY-2, and alters the cortical accumu

255 hain, desmin, vinculin, and laminin, but not non-muscle myosin, vimentin, fibronectin, or type IV col

256 osin phosphatase Pp1 complex, which inhibits non-muscle myosin-II (Myo-II) activity, coordinates bord

257 e contraction of a circumferential actin and non-muscle myosin-II (myosin) belt underlying adherens j

258 rturbations of INM by inhibition of actin or non-muscle myosin-II (NMII) reduced INM measures.

259 d that heavy chain phosphorylation regulates non-muscle myosin-II assembly in an isoform-specific man

260 g associated with an apical concentration of non-muscle myosin.

261 ed that rotatin interacts with the neuronal (non-muscle) myosin heavy chain subunits, motors of nucle

262 Cytoplasmic (or non-muscle) myosin II isoforms are widely expressed mole

263 UNC-45A is a molecular chaperone targeted to non-muscle myosins and is essential for cell division.

264 Parkinson's disease-causing protein DJ-1 and non-muscle myosins as Tau interactors whose binding to T

265 osins have general relevance for cardiac and non-muscle myosins as well as for skeletal muscle.

266 The presence of wild-type Tau stabilized non-muscle myosins at higher steady-state levels.

267 The direct link of Tau to non-muscle myosins corroborates independently proposed r

268 Kinetic adaptation of muscle and non-muscle myosins plays a central role in defining the

269 glial cells, the preferential interaction of non-muscle myosins to wild-type Tau depended on myosin A

270 e a strain-sensitive step in many muscle and non-muscle myosins.

271 few examples of postsynaptic function for a non-muscle nicotinic acetylcholine receptor (nAChR).

272 KEY POINTS: Non-muscle (NM) and smooth muscle (SM) myosin II are bot

273 ABSTRACT: The molecular function of non-muscle (NM) isoforms of myosin II in smooth muscle (

274 S100A4 binds to the heavy chain of non-muscle (NM) myosin II and can regulate the motility

275 ity of metastatic cancer cells by binding to non-muscle (NM) myosin II.

276 tile cardial cells (CCs) and the surrounding non-muscle pericardial cells (PCs), development of which

277 tile markers and appearance of expression of non-muscle proteins ("proliferative phenotype").

278 ts from DM1 patients and mice expressing the non-muscle RBFOX2 isoform, we identified RBFOX2(40)-driv

279 Mice engineered to express the non-muscle RBFOX2(40) isoform in heart via tetracycline-

280 asts (Mb), myotubes (Mt), muscle and diverse non-muscle samples to elucidate the involvement of multi

281 transcription of muscle genes in a range of non-muscle somatic cell nuclei after transplantation to

282 They cause muscle genes of nuclei from non-muscle somatic cells, after injection into oocytes,

283 Myosin 2 from vertebrate smooth muscle or non-muscle sources is in equilibrium between compact, in

284 d tropomyosin isoforms, from both muscle and non-muscle sources, was investigated.

285 ces between the skeletal-muscle-specific and non-muscle-specific frequency matrices for the binding s

286 llite stem cells, leading to derepression of non-muscle-specific genes and p16INK4a, a senescence dri

287 bunits (VIa, VIIa, and VIII) have muscle and non-muscle-specific isoforms, subunit IV contains a lung

288 Herein, we report that upregulation of a non-muscle splice isoform of RNA-binding protein RBFOX2

289 ad functional attenuation of both muscle and non-muscle symptoms.

290 icated in the onset of insulin resistance in non-muscle tissue.

291 Non-muscle tissues that are sensitive to TH, such as the

292 However, gene transfer in non-muscle tissues, mainly the liver, was dramatically r

293 functions have been ascribed to myoferlin in non-muscle tissues.

294 act independently of dystrophin/utrophin in non-muscle tissues.

295 the manifestations of myotonic dystrophy in non-muscle tissues.

296 orms, their promoters and role in muscle and non-muscle tissues.

297 e highly conserved N termini of three short, non-muscle TMs (alpha, gamma, delta-TM) for the two Tmod

298 dependence of this movement, suggesting that non-muscle tropomyosin isoforms exist, at least in part,

299 important N terminus of a short 247-residue non-muscle tropomyosin was determined in an engineered c

300 ion of the high molecular weight isoforms of non-muscle tropomyosin.